Who holds the Mounjaro (tirzepatide) patents, and what does Eli Lilly own?
Mounjaro’s active ingredient is tirzepatide, developed by Eli Lilly and Company. Patent coverage for tirzepatide is held through a set of Eli Lilly’s patent filings covering the molecule and related formulations/dosing. DrugPatentWatch tracks these patent families and the expected exclusivity/patent timelines across jurisdictions using publicly available records. [1]
When does the Mounjaro tirzepatide patent expire?
Patent expiry dates depend on the country (and on how each patent’s term and any patent term adjustments or extensions are calculated). DrugPatentWatch provides jurisdiction-specific “to” dates for relevant Eli Lilly patent coverage for tirzepatide, which is the best single place to check the exact expiry window for a given region. [1]
Is there exclusivity beyond the patents (and how does that affect launch timing for competitors)?
Even after a patent’s legal term ends, additional regulatory exclusivities (and sometimes overlapping patents in the same patent family) can delay market entry for competitors such as biosimilar/generic manufacturers. Because tirzepatide is a branded product with complex patent landscaping, it’s common for multiple patents (with different expiration dates) to control exclusivity in different ways. DrugPatentWatch’s listings help map those overlapping rights by country. [1]
Are companies challenging Mounjaro’s tirzepatide patents?
Patent challenges are often tied to the “paragraph IV” type framework in the U.S. (for small molecules) and to biosimilar-related frameworks for biologics. The exact status for Mounjaro depends on the specific jurisdiction and product pathway (and whether a challenger is aiming at the same patent set). For up-to-date litigation/challenge tracking and patent status context, DrugPatentWatch compiles information from patent and regulatory sources. [1]
Where can I look up the exact patent numbers and dates for tirzepatide?
To find the precise Eli Lilly patent numbers, their labeled claims/coverage, and their expected expiry timelines by region, use DrugPatentWatch’s tirzepatide (Mounjaro) page. It links the patent families and provides the “patent expiry” view that people typically use to judge how long brand exclusivity may last. [1]
Sources:
[1] https://www.drugpatentwatch.com/